Zanubrutinib Monotherapy in Patients With Hemophagocytic Lymphohistiocytosis

Zanubrutinib HLH

This study is a prospective single-arm clinical study, focusing on Hemophagocytic lymphohistocytosis，to evaluate the clinical efficacy and safety of zanubrutinib.

2022-02-01

2023-08-01

2023-08-01

Completed

Early phase I

16

Inclusion Criteria: 1. Unlimited gender, age ≥ 14 years old; 2. HLH was diagnosed according to HLH-04 diagnostic criteria; 3. Before the study, there was no severe liver function injury; Serum creatinine ≤ 1.5 times the upper limit of normal value; 4. Sign informed consent Exclusion Criteria: 1. Allergic to zebutinib; 2. Currently active important cardiovascular diseases with clinical significance; The functions of important organs such as heart and lung unrelated to HLH were seriously abnormal; 3. Known human immunodeficiency virus (HIV) or active hepatitis B (HBV) or hepatitis C (HCV) infection; 4. Pregnant or lactating women and patients of childbearing age who refuse to take appropriate contraceptive measures during this trial; 5. Serious mental illness; 6. Active massive hemorrhage of internal organs; 7. Uncontrollable infection; 8. At the same time, participate in other clinical researchers

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 16, 'type': 'ACTUAL'}}

2024-04-11